Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00853905 · ClinicalTrials.gov registry record · Phase 2
Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?
A Phase 2 study, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT00853905 is a Phase 2 study that has completed, run by Wills Eye. The registered enrollment target is 77 participants.
The verdict
NCT00853905, a Phase 2 study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
The investigators hypothesize that intracameral Triesence during glaucoma surgery will provide lower intraocular pressure through better control of ocular inflammation, thus leading to a more successful filtering procedure.
Interventions
- DRUG Triesence
- DRUG balanced salt solution BSS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00853905
The ClinicalTrials.gov registry entry for NCT00853905 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Triesence is the first listed.
NCT00853905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00853905 about?
NCT00853905 is a clinical study titled "Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?". The investigators hypothesize that intracameral Triesence during glaucoma surgery will provide lower intraocular pressure through better control of ocular inflammation, thus leading to a more successful filtering procedure.
What is the current status of trial NCT00853905?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2009-02. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00853905?
The interventions under investigation include: Triesence (DRUG), balanced salt solution BSS (DRUG).
Who is sponsoring clinical trial NCT00853905?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.